By Colin Kellaher
BioCryst Pharmaceuticals has won U.S. Food and Drug Administration priority review for an application seeking expanded approval of its Orladeyo hereditary-angioedema drug for children ages 2 through 11.
BioCryst on Wednesday said an FDA green light would make Orladeyo the first targeted oral prophylactic therapy for children under the age of 12 with hereditary angioedema, a genetic disorder characterized by recurrent episodes of severe swelling.
The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period. BioCryst said the agency set a target action date of Sept. 12 for the application.
The FDA approved Orladeyo in December 2020 to prevent hereditary-angioedema attacks in patients 12 and older.
BioCryst, a Durham, NC., biotechnology company, earlier this month raised its 2025 global Orladeyo revenue forecast to $580 million to $600 million from a prior range of $535 million to $550 million.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 14, 2025 07:33 ET (11:33 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.